Loading
Antibodies against TIM-3, a checkpoint on exhausted T cells and myeloid cells, tested mostly with PD-1 drugs and in blood cancers.
T-cell immunoglobulin and mucin domain 3 (TIM-3, gene HAVCR2) marks the most exhausted T cells and is also expressed on leukaemic stem cells and myeloid cells. Antibodies such as sabatolimab and cobolimab have been tested with PD-1 blockade in solid tumours and with hypomethylating agents in myelodysplastic syndromes and acute myeloid leukaemia; the STIMULUS programme in MDS did not meet its endpoints, and development is concentrated in combination settings.
Antibodies block TIM-3 binding to galectin-9, phosphatidylserine and CEACAM1, restoring T-cell and innate immune function.
Cobolimab is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for non-small-cell lung cancer, melanoma and hodgkin lymphoma, with its target not yet stated publicly.
Query for this technology: (TITLE:"TIM-3 blockade" OR ABSTRACT:"TIM-3 blockade") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIM-3 blockade, not a curated reading list.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).